Cointime

Constellation Pharmaceuticals

company

About

Constellation Pharmaceuticals develops drugs in the field of epigenetics focusing on selective regulators of its function.

  • 101 - 250

Highlights

Total Funding Amount
$188.50M
Funding Rounds
3
Investors
2

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$40M
Industries
Biotechnology,Genetics,Medical,Pharmaceutical
Founded date
Jan 1, 2008
Number Of Employee
101 - 250
Operating Status
Active

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$188.50M
Constellation Pharmaceuticals has raised a total of $188.50M in funding over 2 rounds. Their latest funding was raised on Mar 20, 2019 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 20, 2019 Post-IPO Debt $40M 1 — — Detail
Apr 9, 2018 Series F $100M 1 — — Detail
Jul 1, 2017 Series E $48.50M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Constellation Pharmaceuticals is funded by 2 investors. Hercules Capital and University of California Investment Office are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital — Post-IPO Debt
University of California Investment Office — Series F
Cointime
เนื้อหา
บริษัท